IP Library Granted Patent US 8,211,880
Granted Patent B2
US 8,211,880 · App. 13/352,009 · Granted Jul 3, 2012

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,211,880
App. No.
13/352,009
Granted
Jul 3, 2012
Kind
B2
Abstract

Triamcinolone acetonide suspension compositions are disclosed. The suspension compositions have a relatively low viscosity and are easy to extrude through a 27- or 30-guage needle but are highly flocculated and easily redispersed. The compositions are particularly suitable for intravitreal injection.

Claims (16)

1. A method of treating an ophthalmic disorder comprising administering by intravitreal injection an aqueous suspension composition, wherein the suspension composition does not contain a preservative, has a pH from 6-7.5, a viscosity from 2-12 cps, and a Degree of Flocculation of 9.5 or greater, and wherein the suspension composition consists essentially of:

a) 4% (w/v) triamcinolone acetonide having a mean volume diameter of 3-10 μm;

b) 0.5% (w/v) sodium carboxymethylcellulose;

c) 0.002-0.015% (w/v) polysorbate 80;

d) one or more pharmaceutically acceptable chloride salts selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, and magnesium chloride as tonicity-adjusting agents in a total amount sufficient to cause the suspension composition to have an osmolality from 250-350 mOsm;

e) water for injection;

f) a buffering agent; and

g) optionally a pH-adjusting agent.

2. A method of enhancing visualization of the vitreous during vitrectomy procedures comprising administering by intravitreal injection an aqueous suspension composition, wherein the suspension composition does not contain a preservative, has a pH from 6-7.5, a viscosity from 2-12 cps, and a Degree of Flocculation of 9.5 or greater, and wherein the suspension composition consists essentially of:

a) 4% (w/v) triamcinolone acetonide having a mean volume diameter of 3-10 μm;

b) 0.5% (w/v) sodium carboxymethylcellulose;

c) 0.002-0.015% (w/v) polysorbate 80;

d) one or more pharmaceutically acceptable chloride salts selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, and magnesium chloride as tonicity-adjusting agents in a total amount sufficient to cause the suspension composition to have an osmolality from 250-350 mOsm;

e) water for injection;

f) a buffering agent; and

g) optionally a pH-adjusting agent.

Assignments (10)
SECURITY INTEREST Recorded Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62452/0106 Recorded Mar 30, 2023
From: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
To: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
Reel/Frame 063206/0156 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
SECURITY INTEREST Recorded Jan 23, 2023
From: HARROW HEALTH, INC.; HARROW IP, LLC; IMPRIMISRX, LLC; HARROW EYE, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
To: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 062452/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2023
From: NOVARTIS AG
To: HARROW IP, LLC
Reel/Frame 062442/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2021
From: ALCON INC.
To: NOVARTIS AG
Reel/Frame 054934/0300 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Jul 23, 2020
From: ALCON RESEARCH, LLC
To: ALCON INC.
Reel/Frame 053293/0484 →
MERGER Recorded Jul 21, 2020
From: ALCON RESEARCH, LTD.
To: ALCON RESEARCH, LLC
Reel/Frame 053273/0022 →
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →